according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

SECTION 1. IDENTIFICATION

Product name : Sitagliptin / Simvastatin Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Combustible dust

Eye irritation : Category 2A

Skin sensitization : Category 1

Carcinogenicity (Inhalation) : Category 2

Specific target organ toxicity

- repeated exposure

Category 1 (Liver, muscle, optic nerve, Eye)

GHS label elements

Hazard pictograms :





Signal Word : Danger

Hazard Statements : If small particles are generated during further processing, han-

dling or by other means, may form combustible dust concentra-

tions in air.

H317 May cause an allergic skin reaction. H319 Causes serious eye irritation.

H351 Suspected of causing cancer if inhaled.

H372 Causes damage to organs (Liver, muscle, optic nerve,

Eye) through prolonged or repeated exposure.

Precautionary Statements : Prevention:

P201 Obtain special instructions before use.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

P202 Do not handle until all safety precautions have been read and understood.

P260 Do not breathe dust.

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product. P272 Contaminated work clothing must not be allowed out of the workplace.

P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P308 + P313 IF exposed or concerned: Get medical attention. P333 + P313 If skin irritation or rash occurs: Get medical attention

P337 + P313 If eye irritation persists: Get medical attention.

P363 Wash contaminated clothing before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

| Chemical name | CAS-No. | Concentration (% w/w) |
|------------------|-------------|-----------------------|
| Sitagliptin | 654671-77-9 | >= 10 - < 20 |
| Cellulose | 9004-34-6 | >= 5 - < 10 |
| Simvastatin | 79902-63-9 | >= 1 - < 5 |
| Starch | 9005-25-8 | >= 1 - < 5 |
| Ascorbic acid | 50-81-7 | >= 1 - < 5 |
| Titanium dioxide | 13463-67-7 | >= 0.1 - < 1 |

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 03/20/2023 09/26/2023 24515-00021 Date of first issue: 10/21/2014 10.1

Get medical attention.

In case of contact, immediately flush skin with plenty of water. In case of skin contact

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact In case of contact, immediately flush eyes with plenty of water

for at least 15 minutes.

If easy to do, remove contact lens, if worn.

Get medical attention.

If swallowed If swallowed, DO NOT induce vomiting.

> Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

May cause an allergic skin reaction.

Causes serious eye irritation.

Suspected of causing cancer if inhaled.

Causes damage to organs through prolonged or repeated

exposure.

First Aid responders should pay attention to self-protection, Protection of first-aiders

> and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides Metal oxides

Oxides of phosphorus

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 09/26/2023 24515-00021 Date of first issue: 10/21/2014 10.1

Avoid release to the environment. Environmental precautions

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable

container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation

Use only with adequate ventilation. Advice on safe handling Do not get on skin or clothing.

> Do not breathe dust. Do not swallow.

Do not get in eyes.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage Keep in properly labeled containers.

Store in accordance with the particular national regulations.

Do not store with the following product types: Materials to avoid

Strong oxidizing agents

Self-reactive substances and mixtures

Organic peroxides

Explosives Gases

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

inert or nuisance dust 50 Million particles per cubic foot

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

15 mg/m³

Value type (Form of exposure): TWA (total dust)

Basis: OSHA Z-3

5 mg/m³

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

15 Million particles per cubic foot

Value type (Form of exposure): TWA (respirable fraction)

Basis: OSHA Z-3

Dust, nuisance dust and par-

ticulates

10 mg/m³

Value type (Form of exposure): PEL (Total dust)

Basis: CAL PEL

5 mg/m³

Value type (Form of exposure): PEL (respirable dust fraction)

Basis: CAL PEL

| Components | CAS-No. | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis | |
|---------------|----------------|-------------------------------------|--|-----------|--|
| Sitagliptin | 654671-77-9 | TWA | 0.5 mg/m3 (OEB 2) | Internal | |
| Cellulose | 9004-34-6 | TWA | 10 mg/m ³ | ACGIH | |
| | | TWA (Respirable) | 5 mg/m³ | NIOSH REL | |
| | | TWA (total) | 10 mg/m³ | NIOSH REL | |
| | | TWA (total dust) | 15 mg/m³ | OSHA Z-1 | |
| | | TWA (respirable fraction) | 5 mg/m³ | OSHA Z-1 | |
| Simvastatin | 79902-63-9 | TWA | 25 μg/m3 (OEB 3) | Internal | |
| | Further inform | Further information: DSEN | | | |
| | | Wipe limit | 250 µg/100 cm ² | Internal | |
| Starch | 9005-25-8 | TWA | 10 mg/m ³ | ACGIH | |
| | | TWA (Respirable) | 5 mg/m³ | NIOSH REL | |
| | | TWA (total) | 10 mg/m ³ | NIOSH REL | |
| | | TWA (total dust) | 15 mg/m³ | OSHA Z-1 | |
| | | TWA (respirable fraction) | 5 mg/m³ | OSHA Z-1 | |
| Ascorbic acid | 50-81-7 | TWA | 5000 μg/m3 (OEB | Internal | |

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/20/2023

 10.1
 09/26/2023
 24515-00021
 Date of first issue: 10/21/2014

| | | | 1) | |
|------------------|------------|--|---------------------------------|----------|
| Titanium dioxide | 13463-67-7 | TWA (total dust) | 15 mg/m³ | OSHA Z-1 |
| | | TWA (Res- pirable par- ticulate mat- ter) | 2.5 mg/m³ (Titanium dioxide) | ACGIH |

Engineering measures : All engineering controls should be implemented by facility

design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face

containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are

unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets,

disposable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke.

Contaminated work clothing should not be allowed out of the

workplace.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version **Revision Date:** SDS Number: Date of last issue: 03/20/2023 09/26/2023 24515-00021 Date of first issue: 10/21/2014 10.1

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance powder

Color pink

Odor No data available

Odor Threshold No data available

No data available pН

Melting point/freezing point No data available

Initial boiling point and boiling

range

No data available

Flash point Not applicable

Evaporation rate Not applicable

Flammability (solid, gas) May form explosive dust-air mixture during processing,

handling or other means.

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure Not applicable

Relative vapor density Not applicable

Relative density No data available

No data available Density

Solubility(ies)

Water solubility No data available

Partition coefficient: n-

octanol/water

Not applicable

Autoignition temperature No data available

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing,

handling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Sitagliptin:

Acute oral toxicity : LD50 (Rat): > 3,000 mg/kg

LD50 (Mouse): 3,000 mg/kg

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Simvastatin:

Acute oral toxicity : LD50 (Rat): 5,000 mg/kg

LD50 (Mouse): 3,800 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Ascorbic acid:

Acute oral toxicity : LD50 (Rat): 11,900 mg/kg

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhala-

tion toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Sitagliptin:

Species : Rabbit
Method : Draize Test
Result : No skin irritation

Simvastatin:

Species : Rabbit

Remarks : Moderate skin irritation

Ascorbic acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/20/2023

 10.1
 09/26/2023
 24515-00021
 Date of first issue: 10/21/2014

Serious eye damage/eye irritation

Causes serious eye irritation.

Components:

Sitagliptin:

Species : Rabbit

Result : Irritating to eyes.
Method : Draize Test

Simvastatin:

Species : Rabbit

Remarks : slight irritation

Starch:

Species : Rabbit

Result : No eye irritation

Ascorbic acid:

Species : Rabbit

Result : No eye irritation

Method : OECD Test Guideline 405

Titanium dioxide:

Species : Rabbit

Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Not classified based on available information.

Components:

Sitagliptin:

Test Type : Local lymph node assay (LLNA)

Species : Mouse

Method : OECD Test Guideline 429
Result : Not a skin sensitizer.

Simvastatin:

Assessment : Probability or evidence of skin sensitization in humans

Result : positive

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Starch:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Ascorbic acid:

Test Type : Maurer optimisation test

Routes of exposure : Skin contact Species : Guinea pig Result : negative

Titanium dioxide:

Test Type : Local lymph node assay (LLNA)

Routes of exposure : Skin contact Species : Mouse Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Sitagliptin:

Genotoxicity in vitro : Test Type: Ames test

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: negative

Test Type: DNA damage and repair, unscheduled DNA syn-

thesis in mammalian cells (in vitro)
Test system: rat hepatocytes

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Application Route: Ingestion

Result: negative

Simvastatin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Alkaline elution assay

Result: negative

Test Type: Chromosomal aberration

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse

Application Route: Oral

Result: negative

Germ cell mutagenicity -

Assessment

Weight of evidence does not support classification as a germ

cell mutagen.

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Ascorbic acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test

Species: Mouse Result: negative

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Carcinogenicity

Suspected of causing cancer if inhaled.

Components:

Sitagliptin:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Species : Rat

Application Route : oral (drinking water)

Exposure time : 2 Years
Result : positive
Target Organs : Liver

Remarks : Significant toxicity observed in testing

Carcinogenicity - Assess-

ment

Weight of evidence does not support classification as a car-

cinogen

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Simvastatin:

Species : Mouse Application Route : Oral

Exposure time : < 92 weeks
Target Organs : Harderian gland
Tumor Type : Liver, Lungs

Remarks : The significance of these findings for humans is not certain.

Species : Rat
Application Route : Oral
Exposure time : 2 Years
Tumor Type : Liver, Thyroid

Remarks : The significance of these findings for humans is not certain.

Ascorbic acid:

Species: MouseApplication Route: IngestionExposure time: 2 YearsResult: negative

Titanium dioxide:

Species : Rat

Application Route : inhalation (dust/mist/fume)

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : positive

Remarks : The mechanism or mode of action may not be relevant in hu-

mans.

Carcinogenicity - Assess-

ment

Limited evidence of carcinogenicity in inhalation studies with

animals.

IARC Group 2B: Possibly carcinogenic to humans

Titanium dioxide 13463-67-7

OSHA No component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Sitagliptin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Oral

Fertility: NOAEL Parent: 1,000 mg/kg body weight Result: Animal testing did not show any effects on fertility.

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Teratogenicity: LOAEL: 250 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected., No teratogenic effects.

Test Type: Embryo-fetal development

Species: Rabbit

Teratogenicity: NOAEL: 125 mg/kg body weight

Result: No teratogenic effects.

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Simvastatin:

Effects on fertility : Test Type: Fertility

Species: Rat, male Application Route: Oral

Fertility: LOAEL: 25 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 25 mg/kg body weight Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development

Species: Rabbit Application Route: Oral

Embryo-fetal toxicity.: NOAEL: 10 mg/kg body weight Result: No teratogenic effects., No adverse effects.

Test Type: Embryo-fetal development

Species: Rat

Application Route: Oral

Embryo-fetal toxicity.: LOAEL: 60 mg/kg body weight

Result: Teratogenic potential.

Remarks: Based on data from similar materials

Ascorbic acid:

Effects on fetal development : Test Type: Embryo-fetal development

Species: Rat

Application Route: Ingestion

Result: negative

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

Causes damage to organs (Liver, muscle, optic nerve, Eye) through prolonged or repeated exposure.

Components:

Simvastatin:

Target Organs : Liver, muscle, optic nerve, Eye

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Sitagliptin:

Species : Mouse NOAEL : 500 mg/kg

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

LOAEL : 1,000 mg/kg

Application Route : Oral
Exposure time : > 2 y
Target Organs : Kidney

Species : Rat

NOAEL : 500 mg/kg

LOAEL : 1,000 mg/kg

Application Route : Oral

Exposure time : 14 Weeks

Target Organs : Liver, Kidney, Heart, Teeth

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral
Exposure time : 53 Weeks

Target Organs : Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Dog
NOAEL : 2 mg/kg
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 27 Weeks

Target Organs : Skeletal muscle, Central nervous system

Symptoms : Loss of balance

Remarks : The mechanism or mode of action may not be relevant in

humans.

Species : Monkey
NOAEL : 100 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Remarks : No significant adverse effects were reported

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg
Application Route : Ingestion
Exposure time : 90 Days

Simvastatin:

Species : Rat

NOAEL : 5 mg/kg

LOAEL : 30 mg/kg

Application Route : Oral

Exposure time : 14 - 104 Weeks

Target Organs : Liver, Testis, Musculo-skeletal system, Eye

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Species : Dog LOAEL : 10 mg/kg Application Route : Oral

Exposure time : 14 - 104 Weeks
Target Organs : Liver, Testis, Eye

Species : Rabbit
NOAEL : 30 mg/kg
LOAEL : 50 mg/kg
Application Route : Oral

Target Organs : Liver, Kidney

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days

Method : OECD Test Guideline 410

Ascorbic acid:

Species : Rat, male

NOAEL : >= 8,100 mg/kg

Application Route : Ingestion

Exposure time : 13 Weeks

Titanium dioxide:

Species : Rat

NOAEL : 24,000 mg/kg Application Route : Ingestion Exposure time : 28 Days

Species : Rat NOAEL : 10 mg/m³

Application Route : inhalation (dust/mist/fume)

Exposure time : 2 y

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Sitagliptin:

Inhalation : Symptoms: upper respiratory tract infection, pharyngitis,

Headache

Ingestion : Symptoms: upper respiratory tract infection, nasopharyngitis,

Headache, Nausea, Abdominal pain, Diarrhea

Simvastatin:

Skin contact : Remarks: May produce an allergic reaction.

Ingestion : Target Organs: Liver

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Symptoms: upper respiratory tract infection, Headache, Ab-

dominal pain, constipation, Nausea Target Organs: Musculo-skeletal system

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Sitagliptin:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 60 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 39

mg/

Exposure time: 96 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 2.2

mg/l

Exposure time: 96 h

Method: OECD Test Guideline 201

Toxicity to fish (Chronic tox-

icity)

NOEC (Pimephales promelas (fathead minnow)): 9.2 mg/l

Exposure time: 33 d

Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 9.8 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 150 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 150 mg/l Exposure time: 3 h

Test Type: Respiration inhibition

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Simvastatin:

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.91 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 3.5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 25

mg/l

Exposure time: 96 h

NOEC (Pseudokirchneriella subcapitata (green algae)): 25

mq/l

Exposure time: 96 h

Toxicity to microorganisms : EC50: > 30 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 21 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Ascorbic acid:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 1,020 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to microorganisms : EC50: 140 mg/l

Exposure time: 16 h Method: DIN 38 412 Part 8

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l

Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

Persistence and degradability

Components:

Sitagliptin:

Biodegradability : Result: not rapidly degradable

Biodegradation: 39.7 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(401 d)

Method: OECD Test Guideline 111

Cellulose:

Biodegradability : Result: Readily biodegradable.

Simvastatin:

Biodegradability : Result: rapidly degradable

Stability in water : Hydrolysis: 50 %(3.2 d)

Ascorbic acid:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 5 d

Method: OECD Test Guideline 302

Bioaccumulative potential

Components:

Sitagliptin:

Partition coefficient: n-

octanol/water

log Pow: -0.03

Simvastatin:

Partition coefficient: n-

octanol/water

: log Pow: > 4.07

Ascorbic acid:

Partition coefficient: n-

: log Pow: -1.85

octanol/water

Mobility in soil

Components:

Sitagliptin:

Distribution among environ-

mental compartments

log Koc: 4.37

Other adverse effects

No data available

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust

Respiratory or skin sensitization

Carcinogenicity

Specific target organ toxicity (single or repeated exposure)

Serious eye damage or eye irritation

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

US State Regulations

Pennsylvania Right To Know

D-Glucose, 4-O- β -D-galactopyranosyl-, monohydrate 64044-51-5 Calcium hydrogenorthophosphate 7757-93-9 Sitagliptin 654671-77-9 Cellulose 9004-34-6 Starch 9005-25-8 Simvastatin 79902-63-9

California Prop. 65

WARNING: This product can expose you to chemicals including Titanium dioxide, which is/are known to the State of California to cause cancer. For more information go to www.P65Warnings.ca.gov.

California Permissible Exposure Limits for Chemical Contaminants

 Cellulose
 9004-34-6

 Starch
 9005-25-8

The ingredients of this product are reported in the following inventories:

AICS : not determined


DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION


Further information

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 03/20/2023 10.1 09/26/2023 24515-00021 Date of first issue: 10/21/2014

CAL PEL : California permissible exposure limits for chemical contami-

nants (Title 8, Article 107)

NIOSH REL : USA. NIOSH Recommended Exposure Limits

OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Lim-

its for Air Contaminants

OSHA Z-3 : USA. Occupational Exposure Limits (OSHA) - Table Z-3 Min-

eral Dusts

ACGIH / TWA : 8-hour, time-weighted average CAL PEL / PEL : Permissible exposure limit

NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour

workday during a 40-hour workweek

OSHA Z-1 / TWA : 8-hour time weighted average OSHA Z-3 / TWA : 8-hour time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC -International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Compile the Material Salety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 09/26/2023

according to the OSHA Hazard Communication Standard



Sitagliptin / Simvastatin Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 03/20/2023

 10.1
 09/26/2023
 24515-00021
 Date of first issue: 10/21/2014

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8